Home » Stocks » TRIB

Trinity Biotech PLC (TRIB)

Stock Price: $4.62 USD 0.08 (1.76%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 94.89M
Revenue (ttm) 90.44M
Net Income (ttm) -28.91M
Shares Out 96.16M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.62
Previous Close $4.54
Change ($) 0.08
Change (%) 1.76%
Day's Open 4.57
Day's Range 4.42 - 4.74
Day's Volume 271,097
52-Week Range 0.62 - 4.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

DUBLIN, Ireland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved CE Mark approval and registration for its Covid-19 IgG ELISA antibody test, the Captia™ SARS-...

Insider Monkey - 1 month ago

Is Trinity Biotech plc (NASDAQ:TRIB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of to...

Seeking Alpha - 2 months ago

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

DUBLIN, Ireland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory...

GlobeNewsWire - 2 months ago

Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN Conference Call Scheduled for November 17, 2020 at 11:00 am EASTERN

Seeking Alpha - 4 months ago

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

DUBLIN, Ireland, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...

GlobeNewsWire - 5 months ago

Conference Call Scheduled for August 25, 2020 at 11:00am EASTERN Conference Call Scheduled for August 25, 2020 at 11:00am EASTERN

Benzinga - 5 months ago

Trinity Biotech (NASDAQ: TRIB) shares are trading lower on Monday after the company's subsidiary Primus Corp announced it received an FDA warning letter following an inspection of Kansas City ...

GlobeNewsWire - 5 months ago

DUBLIN, Ireland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...

Seeking Alpha - 7 months ago

Trinity Biotech's (TRIB) CEO Ronan O'Caoimh on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborator...

Seeking Alpha - 9 months ago

Trinity Biotech plc's (TRIB) CEO Ronan O'Caoimh on Q4 2019 Results - Earnings Call Transcript

24/7 Wall Street - 9 months ago

Trinity Biotech PLC (NASDAQ: TRIB) released its fiscal fourth-quarter financial results on Tuesday morning, but that wasn’t what propelled the stock afterward.

Investopedia - 10 months ago

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Other stocks mentioned: BNTC, SUPV
GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...

Seeking Alpha - 1 year ago

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

DUBLIN, Ireland, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laborato...

Seeking Alpha - 1 year ago

For more than five years, shares of Trinity Biotech have woefully under-performed peers and the market.

Seeking Alpha - 1 year ago

Trinity Biotech PLC (TRIB) CEO Ronan O'Caoimh on Q1 2019 Results - Earnings Call Transcript

About TRIB

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathog... [Read more...]

Industry
Diagnostics & Research
Founded
1992
CEO
Ronan O'Caoimh
Employees
579
Stock Exchange
NASDAQ
Ticker Symbol
TRIB
Full Company Profile

Financial Performance

In 2019, TRIB's revenue was $90.44 million, a decrease of -6.80% compared to the previous year's $97.04 million. Losses were -$28.91 million, 30.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for TRIB stock is "Strong Buy" and the 12-month stock price forecast is 7.00.

Price Target
$7.00
Analyst Consensus: Strong Buy